Alexander Drilon, MD

Alexander Drilon, MD, is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center

Articles

Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD

September 18th 2025

Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors

October 30th 2024

Dr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.

Dr Drilon on Efficacy Results With Taletrectinib in ROS1+ NSCLC

October 23rd 2024

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC

December 5th 2023

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Dr. Drilon on the FDA Approval of Selpercatinib in RET Fusion+ Solid Tumors

November 17th 2022

Alexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.

Rapid Readouts: Larotrectinib Prior Therapy and Performance Status Outcomes in Patients With Non-CNS TRK Fusion Cancer

November 1st 2021

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.

Rapid Readouts: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

November 1st 2021

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Dr. Drilon on the Utility of Brigatinib in ALK+ NSCLC

January 31st 2020

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

Dr. Drilon on the Utility of Immunotherapy in ALK+ NSCLC

January 24th 2020

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

Dr. Drilon on the Safety Profile of Brigatinib in ALK+ NSCLC

January 10th 2020

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

Dr. Drilon on Treatment Selection Considerations in ALK+ NSCLC

December 12th 2019

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Dr. Drilon on Comprehensive Sequencing in Lung Cancer

November 26th 2019

Alexander Drilon, MD, discusses performing comprehensive sequencing in lung cancer.

Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial

September 10th 2019

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Dr. Drilon on Emerging Biomarkers in NSCLC

January 5th 2019

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Dr. Drilon Discusses the FDA Approval of Larotrectinib

November 27th 2018

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

Dr. Drilon Discusses Efficacy Results With LOXO-292 in RET-Altered Solid Tumors

June 5th 2018

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses findings from the phase I LIBRETTO-001 study exploring the highly selective RET inhibitor LOXO-292 in patients with RET-altered solid tumors.

Dr. Drilon on Targeted Therapies for Patients With ROS1-Rearranged Lung Cancer

April 18th 2018

Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.

Dr. Drilon Discusses CNS Penetration in NSCLC

November 10th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system penetration in the treatment of non-small cell lung cancer.

Dr. Drilon on MET-Amplified Lung Cancer

October 25th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.